Gilead has agreed to accumulate Arcellx in a deal value $7.8bn, because the drugmaker appears so as to add a CAR T-cell remedy for blood most cancers therapy on the cusp of approval to its portfolio.
As per the settlement, Gilead can pay $115 per share, in addition to a one contingent worth proper of $5 every. The deal is anticipated to shut in Q2 2026.
The acquisition marks the fruits of a interval of collaboration between the 2 firms. In 2022, Gilead, by way of its subsidiary Kite, entered a analysis and growth partnership with Arcellx to advance the latter’s anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell remedy for sufferers with a number of myeloma. Gilead had invested within the biotech as a part of the association and, having injected additional money in 2023, at the moment holds a 11.5% share in Arcellx.
Anito-cel, delivered ex vivo, is at the moment underneath assessment by the US Meals and Drug Administration (FDA), with an anticipated Prescription Drug Consumer Payment Act (PDUFA) motion date of 23 December 2026. If authorised, it is going to be out there as a fourth-line therapy for sufferers with relapsed or refractory a number of myeloma. The $5 contingent worth proper (CVR) included within the acquisition will likely be paid out if world anito-cel gross sales hit $6bn by the tip of 2029.
In a analysis be aware, William Blair analysts stated: “We additionally mannequin anito-cel reaching $7.8bn in cumulative world gross sales by year-end 2029, subsequently we view the CVR as more likely to be achieved.”
Gilead’s CEO Daniel O’Day stated: “This settlement displays our conviction within the potential of anito-cel and our intention to maneuver with velocity so we are able to profit from that potential for sufferers with a number of myeloma.
“Past the potential launch this 12 months, anito-cel might turn into a foundational therapy for a number of myeloma over time, together with earlier strains of remedy. As well as, the anito-cel D-domain BCMA binder may very well be necessary to our work in in vivo cell remedy, additional strengthening our potential in oncology and irritation,” O’Day added.
CAR T is a sort of personalised immunotherapy that treats sure blood cancers by reprogramming a affected person’s personal T-cells to recognise and destroy most cancers cells. Whereas all authorised CAR-T merchandise are ex vivo, pharma curiosity towards in vivo cell therapies has grown, which some buyers are touting as the way forward for CGT. This route of supply has dominated M&A exercise within the CAR-T area up to now 12 months.
The newest large pharma firm to ink a deal was Eli Lilly, which acquired Orna Therapeutics and its vary of round RNA (circRNA) and lipid nanoparticle-based therapies for $2.4bn in February 2026. Bristol Myers Squibb (BMS) made an analogous transfer by laying out $1.5bn to accumulate Orbital Therapeutics and its investigational, RNA-based in vivo CAR-T medicines in October 2025. In July 2025, AbbVie made an in vivo play by its $2.1bn, “high-risk, high-reward” buyout of Capstan Therapeutics. In contrast to many firms within the area, that are centered on growing CAR Ts for oncology, Capstan is progressing its pipeline of in vivo therapeutics for the therapy of B-cell mediated autoimmune ailments.
